Lymphokine activated killer cells

Drug Profile

Lymphokine activated killer cells

Latest Information Update: 15 Aug 2007

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Chiron Corporation; Nonindustrial source
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Hepatocellular carcinoma; Leukaemia; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Solid tumours; Viral infections

Most Recent Events

  • 01 Sep 2000 Clinical trials in Leukaemia in Italy (Infusion)
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 15 Mar 1999 Clinical trials in Cancer in Japan (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top